Jesse A. Jones

TL;DR: Recent advances in employing engineered encapsulins across various fields are discussed, from their use as bionanoreactors to targeted delivery systems and beyond, with a special focus on the rational engineering of encapsulin systems.

TL;DR: Evaluated the enoyl-acyl carrier protein (ACP) reductase II (FabK), which catalyzes the final step of bacterial fatty acid biosynthesis, and suggests that C. difficile FabK is a druggable target for discovering narrow-spectrum anti- C. Difficile drugs that treat CDI but avoid collateral damage to the gut microbiota.

TL;DR: This review discusses next-generation antibacterial agents developed using rational, or targeted, drug design strategies that have been designed to bypass developing bacterial resistance, improve the antibacterial spectrum of activity, and/or to optimize other properties, including physicochemical and pharmacokinetic properties.

TL;DR: The determined structure has allowed insight into the structural basis for the NADPH dependence observed in PgFabK and the role of a monovalent cation that has been observed in previous studies to be stringently required for FabK activity to facilitate structure-based drug-discovery efforts towards the prevention and treatment of P. gingivalis infection.

TL;DR: In this article, a peptide capable of triggering conformational change at a key structural position in the largest known encapsulin nanocompartment is introduced, and the structure of the resulting engineered nanocage is reported.